Read further: Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin: A Cohort Study
Most Recent Articles
Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci
This study aimed to address the concerns surrounding the genetic sequence variants of angiotensin-converting enzyme inhibitor (ACEi) discontinuation and its association with ACEI-associated adverse drug reactions (ADRs). Here...
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin: A Cohort Study
Recent clinical studies have shown that the usage of SGLT-2i has cardioprotective advantages. In light of this, recent recommendations urge individuals with type 2 diabetes and concomitant cardiovascular disease to use SGLT-2i as...
Starting SLGT2 Inhibitors Early In Chronic Heart Failure Patients
Acute heart failure (HF) remains to be a particular point of concern among health experts despite advances in medical therapy over the years. Acute HF currently maintains a high rate of morbidity and mortality (Tromp et al, 2020)...
Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): A randomised controlled trial
Lifestyle changes are among some of the easily-mentioned steps in preventing the onset of cardiovascular disease, known to be the leading cause of death around the world. Despite this, many questions surround the aspect of...